Sapropterin dihydrochloride for phenylketonuria and tetrahydrobiopterin deficiency

References

• Blau N, Belanger-Quintana A, Demirkol M et al. Optimizing the use of sapropterin (BH(4)) in the management of phenylketonuria. Mol. Genet. Metab.96(4), 158–163 (2009).
   PubMed Web of Science ®Google Scholar
• Scriver CR. The PAH gene, phenylketonuria, and a paradigm shift. Hum. Mutat.28(9), 831–845 (2007).
   PubMed Web of Science ®Google Scholar
• Guttler F, Guldberg P. Mutations in the phenylalanine hydroxylase gene: genetic determinants for the phenotypic variability of hyperphenylalaninemia. Acta Paediatr. Suppl.407, 49–56 (1994).
   Google Scholar
• Feillet F, van Spronsen FJ, Macdonald A et al. Challenges and pitfalls in the management of phenylketonuria. Pediatrics (2010) (In press).
   Google Scholar
• Lindner M. Treatment of phenylketonuria variants: European recommendations. In: PKU and BH4: Advances in Phenylketonuria and Tetrahydrobiopterin. Blau N (Ed.). SPS Verlagsgesellschaft mbH, Heilbronn, Germany 180–187 (2006).
   Google Scholar
• Huttenlocher PR. The neuropathology of phenylketonuria: human and animal studies. Eur. J. Pediatr.159(Suppl. 2), S102–S106 (2000).
   PubMedGoogle Scholar
• NIH. National Institutes of Health Consensus Development Conference Statement: phenylketonuria: screening and management, October 16–18, 2000. Pediatrics108(4), 972–982 (2001).
   PubMed Web of Science ®Google Scholar
• Hegge KA, Horning KK, Peitz GJ, Hegge K. Sapropterin: a new therapeutic agent for phenylketonuria. Ann. Pharmacother.43(9), 1466–1473 (2009).
   Google Scholar
• Scriver CR, Kaufman S. Hyperphenylalanemia: phenylalanine hydroxylase deficiency. In: The Metabolic and Molecular Bases of Inherited Disease. Scriver CR, Beaudet AL, Sly WS, Valle D (Eds). McGraw-Hill, NY, USA 1667–1709 (2001).
   Google Scholar
• Arnold GL, Vladutiu CJ, Orlowski CC, Blakely EM, DeLuca J. Prevalence of stimulant use for attentional dysfunction in children with phenylketonuria. J. Inherit. Metab. Dis.27(2), 131–143 (2004).
   Google Scholar
• Gassio R, Fuste E, Lopez-Sala A, Artuch R, Vilaseca MA, Campistol J. School performance in early and continuously treated phenylketonuria. Pediatr. Neurol.33(4), 267–271 (2005).
   Google Scholar
• Waisbren SE, Noel K, Fahrbach K et al. Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis. Mol. Genet. Metab.92(1–2), 63–70 (2007).
   PubMed Web of Science ®Google Scholar
• White DA, Tabor Connor L, Nardos B et al. Age-related decline in the microstructural integrity of white matter in children with early- and continuously-treated PKU: a DTI study of the corpus callosum. Mol. Genet. Metab.99(Suppl. 1), S41–S46 (2010).
   PubMedGoogle Scholar
• Hoeks MP, den Heijer M, Janssen MC. Adult issues in phenylketonuria. Neth. J. Med.67(1), 2–7 (2009).
   PubMed Web of Science ®Google Scholar
• Loeber JG. Neonatal screening in Europe; the situation in 2004. J. Inherit. Metab. Dis.30(4), 430–438 (2007).
   PubMed Web of Science ®Google Scholar
• O’Neill CA, Eisensmith RC, Croke DT, Naughten ER, Cahalane SF, Woo SL. Molecular analysis of PKU in Ireland. Acta Paediatr. Suppl.407, 41–44 (1994).
   Google Scholar
• Ozalp I, Coskun T, Tokatli A et al. Newborn PKU screening in Turkey: at present and organization for future. Turk. J. Pediatr.41(2), 97–101 (2001).
   Google Scholar
• Abu Shahla AN, Abed Y, Abu Shahla NK. Screening programme for phenylketonuria in the Gaza Strip: evaluation and recommendations. J. Trop. Pediatr.50(2), 101–105 (2004).
   Google Scholar
• Guldberg P, Henriksen KF, Sipila I, Guttler F, de la Chapelle A. Phenylketonuria in a low incidence population: molecular characterisation of mutations in Finland. J. Med. Genet.32(12), 976–978 (1995).
   PubMed Web of Science ®Google Scholar
• Giovannini M, Verduci E, Salvatici E, Fiori L, Riva E. Phenylketonuria: dietary and therapeutic challenges. J. Inherit. Metab. Dis.30(2), 145–152 (2007).
   PubMed Web of Science ®Google Scholar
• Abadie V, Berthelot J, Feillet F et al. Management of phenylketonuria and hyperphenylalaninemia: the French guidelines. Arch. Pediatr.12(5), 594–601 (2005).
   Google Scholar
• Bremer H, Buhrdel P, Burgard P et al. Therapie von patienten mit phenylkentonuria. Empfehlungen der Arbeitsgemeinschaft für pädiatrische stoffwechselstörungen (in German). Monatsschr. Kinderheilkd.145, 961–962 (1997).
   Google Scholar
• Burgard P, Bremer HJ, Buhrdel P et al. Rationale for the German recommendations for phenylalanine level control in phenylketonuria 1997. Eur. J. Pediatr.158(1), 46–54 (1999).
   Google Scholar
• UK MRC. Recommendations on the dietary management of phenylketonuria. Report of Medical Research Council Working Party on Phenylketonuria. Arch. Dis. Child.68, 426–427 (1993).
   PubMed Web of Science ®Google Scholar
• Walter JH, White FJ, Hall SK et al. How practical are recommendations for dietary control in phenylketonuria? Lancet360(9326), 55–57 (2002).
   PubMed Web of Science ®Google Scholar
• Koch R, Burton B, Hoganson G et al. Phenylketonuria in adulthood: a collaborative study. J. Inherit. Metab. Dis.25(5), 333–346 (2002).
   PubMed Web of Science ®Google Scholar
• Acosta PB, Yannicelli S, Singh RH, Elsas LJ, Mofidi S, Steiner RD. Iron status of children with phenylketonuria undergoing nutrition therapy assessed by transferrin receptors. Genet. Med.6(2), 96–101 (2004).
   Google Scholar
• Koletzko B, Sauerwald T, Demmelmair H et al. Dietary long-chain polyunsaturated fatty acid supplementation in infants with phenylketonuria: a randomized controlled trial. J. Inherit. Metab. Dis.30(3), 326–332 (2007).
   Google Scholar
• Przyrembel H, Bremer HJ. Nutrition, physical growth, and bone density in treated phenylketonuria. Eur. J. Pediatr.159(Suppl. 2), S129–S135 (2000).
   Google Scholar
• Acosta PB, Yannicelli S, Singh R et al. Nutrient intakes and physical growth of children with phenylketonuria undergoing nutrition therapy. J. Am. Diet. Assoc.103(9), 1167–1173 (2003).
   PubMedGoogle Scholar
• Modan-Moses D, Vered I, Schwartz G et al. Peak bone mass in patients with phenylketonuria. J. Inherit. Metab. Dis.30(2), 202–208 (2007).
   PubMed Web of Science ®Google Scholar
• Kure S, Hou DC, Ohura T et al. Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. J. Pediatr.135(3), 375–378 (1999).
   PubMed Web of Science ®Google Scholar
• Fiege B, Blau N. Assessment of tetrahydrobiopterin (BH4) responsiveness in phenylketonuria. J. Pediatr.150(6), 627–630 (2007).
   PubMed Web of Science ®Google Scholar
• LaClair CE, Ney DM, MacLeod EL, Etzel MR. Purification and use of glycomacropeptide for nutritional management of phenylketonuria. J. Food Sci.74(4), E199–E206 (2009).
   PubMed Web of Science ®Google Scholar
• Matalon R, Surendran S, Matalon KM et al. Future role of large neutral amino acids in transport of phenylalanine into the brain. Pediatrics112(6 Pt 2), 1570–1574 (2003).
   PubMedGoogle Scholar
• Sarkissian CN, Shao Z, Blain F et al. A different approach to treatment of phenylketonuria: phenylalanine degradation with recombinant phenylalanine ammonia lyase. Proc. Natl Acad. Sci. USA96(5), 2339–2344 (1999).
   PubMed Web of Science ®Google Scholar
• Ding Z, Harding C, Rebuffat A, Elzaouk L, Wolff J, Thony B. Correction of murine PKU following AAV-mediated intramuscular expression of a complete phenylalanine hydroxylating system. Mol. Ther.16(4), 673–681 (2008).
   PubMed Web of Science ®Google Scholar
• Harding C. Progress toward cell-directed therapy for phenylketonuria. Clin. Genet.74(2), 97–104 (2008).
   PubMed Web of Science ®Google Scholar
• Yildirim S, Tokatli A, Yilmaz E, Coskun T. Assessment of tetrahydrobiopterin responsiveness in Turkish hyperphenylalaninemic patients. Turk. J. Pediatr.49(1), 1–6 (2007).
   Google Scholar
• Zurfluh MR, Zschocke J, Lindner M et al. Molecular genetics of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. Hum. Mutat.29(1), 167–175 (2008).
   PubMed Web of Science ®Google Scholar
• Burton BK, Grange DK, Milanowski A et al. The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a Phase II, multicentre, open-label, screening study. J. Inherit. Metab. Dis.30(5), 700–707 (2007).
   PubMed Web of Science ®Google Scholar
• Karacić I, Meili D, Sarnavka V et al. Genotype-predicted tetrahydrobiopterin (BH4)-responsiveness and molecular genetics in Croatian patients with phenylalanine hydroxylase (PAH) deficiency. Mol. Genet. Metab.97(3), 165–171 (2009).
   PubMed Web of Science ®Google Scholar
• Thony B, Blau N. Mutations in the BH4-metabolizing genes GTP cyclohydrolase I, 6-pyruvoyl-tetrahydropterin synthase, sepiapterin reductase, carbinolamine-4a-dehydratase, and dihydropteridine reductase. Hum. Mutat.27(9), 870–878 (2006).
   PubMed Web of Science ®Google Scholar
• Blau N, Bonafe L, Blaskovics M. Disorders of phenylalanine and tetrahydrobiopterin metabolism. In: Physician’s Guide to the Laboratory Diagnosis of Metabolic Diseases. Blau N, Duran M, Blaskovics M, Gibson KM (Eds). Springer, Heidelberg, Germany 89–106 (2005).
   Google Scholar
• Blau N, Erlandsen H. The metabolic and molecular bases of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. Mol. Genet. Metab.82(2), 101–111 (2004).
   PubMed Web of Science ®Google Scholar
• Pey AL, Perez B, Desviat LR et al. Mechanisms underlying responsiveness to tetrahydrobiopterin in mild phenylketonuria mutations. Hum. Mutat.24(5), 388–399 (2004).
   PubMedGoogle Scholar
• Gersting SW, Kemter KF, Staudigl M et al. Loss of function in phenylketonuria is caused by impaired molecular motions and conformational instability. Am. J. Hum. Genet.83(1), 5–17 (2008).
   Google Scholar
• Erlandsen H, Pey AL, Gamez A et al. Correction of kinetic and stability defects by tetrahydrobiopterin in phenylketonuria patients with certain phenylalanine hydroxylase mutations. Proc. Natl. Acad. Sci. USA101(48), 16903–16908 (2004).
   PubMed Web of Science ®Google Scholar
• Hayashi T, Ogata A, Takeshisha M et al. Studies on the metabolism and disposition of sapropterin hydrochloride (SUN 0588) l-erythro-tetrahydrobiopterin hydrochloride in rats. Kisho to Rinsho (Basic and Clinical Medicine)26(8), 1–31 (1992).
   Google Scholar
• Feillet F, Clarke L, Meli C et al. Pharmacokinetics of sapropterin in patients with phenylketonuria. Clin. Pharmacokinet.47(12), 817–825 (2008).
   PubMed Web of Science ®Google Scholar
• Fiege B, Ballhausen D, Kierat L et al. Plasma tetrahydrobiopterin and its pharmacokinetic following oral administration. Mol. Genet. Metab.81(1), 45–51 (2004).
   PubMed Web of Science ®Google Scholar
• Shintaku H, Kure S, Ohura T et al. Long-term treatment and diagnosis of tetrahydrobiopterin-responsive hyperphenylalaninemia with a mutant phenylalanine hydroxylase gene. Pediatr. Res.55(3), 425–430 (2004).
   PubMedGoogle Scholar
• Levy HL, Milanowski A, Chakrapani A et al. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a Phase III randomised placebo-controlled study. Lancet370(9586), 504–510 (2007).
   PubMed Web of Science ®Google Scholar
• Musson DG, Kramer WG, Foehr E et al. Relative bioavailability of sapropterin from intact and dissolved sapropterin dihydrochloride tablets and the effects of food: a randomized, open-label, crossover study in healthy adults. Clin. Ther.32(2), 338–346 (2010).
   PubMed Web of Science ®Google Scholar
• Kuster T, Matasovic A, Niederwieser A. Application of gas chromatography-mass spectrometry to the study of biopterin metabolism in man. Detection of biolumazine and 2´-deoxysepialumazine. J. Chromatogr.290, 303–310 (1984).
   Google Scholar
• Niederwieser A, Matasovic A, Kuster T, Staudenmann W, Pfleiderer W, Scheibenreiter S. Catabolism of tetrahydrobiopterin in man. In: Chemistry and Biology of Pteridines. Cooper BA, Whitehead VM (Eds). Walter de Gruyter, Berlin, Germany 305–308 (1986).
   Google Scholar
• Hoshiga M, Hatakeyama K, Watanabe M, Shimada M, Kagamiyama H. Autoradiographic distribution of [14C tetrahydrobiopterin and its developmental change in mice. J. Pharmacol. Exp. Ther.267(2), 971–978 (1993).
   PubMed Web of Science ®Google Scholar
• Nielsen JB, Nielsen KE, Guttler F. Tetrahydrobiopterin responsiveness after extended loading test of 12 Danish PKU patients with the Y414C mutation. J. Inherit. Metab. Dis.33(1), 9–16 (2010).
   Google Scholar
• Wasserstein M, Burton B, Cederbaum S et al. Results of a Phase II, multicenter, open-label study of sapropterin dihydrochloride in subjects with hyperphenylalaninemia related to primary BH4 deficiency. Presented at: The Annual Meeting of the American Society for Human Genetics (ASHG), 2008. PA, USA, 11–15 November 2008.
   Google Scholar
• Lee P, Treacy EP, Crombez E et al. Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuria. Am. J. Med. Genet. A146A(22), 2851–2859 (2008).
   PubMed Web of Science ®Google Scholar
• Trefz FK, Burton BK, Longo N et al. Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a Phase III, randomized, double-blind, placebo-controlled study. J. Pediatr.154(5), 700–707 (2009).
   PubMed Web of Science ®Google Scholar
• Fernhoff PM, Burton B, Nowacka M, Hennerman J, Kakkis ED, Dorenbaum A. PKU 008: a long-term, open-label study of sapropterin dihydrochloride (Kuvan®) in PKU subjects. Presented at: The American College of Medical Genetics Annual Meeting. FL, USA, 25–29 March 2009.
   Google Scholar
• Champigneulle A, Gasteyger C, Bettiol E, Villemagne H, Nespithal K, Bassett R. The Kuvan® Adult Maternal Pediatric European Registry (KAMPER): a long-term observational study of patients with hyperphenylalaninemia treated with Kuvan®. Presented at: The 11th International Congress on Inborn Errors of Metabolism. CA, USA, 29 August–2 September 2009 (Abstract 195).
   Google Scholar
• Kurczynski T, Nicely H, Wuebbels B, Reilly D, Pallansch P. Long-Term observations of PKU patients treated with Kuvan®: an introduction to the PKUDOS registry; and its subregistry PKU MOMS for pregnant or nursing PKU patients [abstract]. Presented at: The American College of Medical Genetics Annual Meeting. FL, USA, 25–29 March 2009.
   Google Scholar
• Asubio. Asubio Pharma Company. Press release (2008).
   Google Scholar
• Blau N, Belanger-Quintana A, Demirkol M et al. Management of phenylketonuria in Europe: Survey results from 19 countries. Mol. Genet. Metab.99(2), 109–115 (2009).
   Google Scholar
• Blau N. Defining tetrahydrobiopterin (BH4)-responsiveness in PKU. J. Inherit. Metab. Dis.31(1), 2–3 (2008).
   Google Scholar
• Levy H, Burton B, Cederbaum S, Scriver C. Recommendations for evaluation of responsiveness to tetrahydrobiopterin (BH(4)) in phenylketonuria and its use in treatment. Mol. Genet. Metab.92(4), 287–291 (2007).
   PubMed Web of Science ®Google Scholar
• Muntau AC, Röschinger W, Habich M et al. Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria. N. Engl. J. Med.347, 2122–2132 (2002).
   PubMed Web of Science ®Google Scholar
• Ponzone A, Porta F, Mussa A, Alluto A, Ferraris S, Spada M. Unresponsiveness to tetrahydrobiopterin of phenylalanine hydroxylase deficiency. Metabolism59, 645–652 (2009).
   Google Scholar